Stock CRL CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Valuation Charles River Laboratories International, Inc.

Equities

CRL

US1598641074

Market Closed - Nyse
Other stock markets
 21:00:02 13/09/2024 BST 		5-day change 1st Jan Change
198.61 USD +2.21% Intraday chart for Charles River Laboratories International, Inc. +5.67% -15.99%
09-10 Transcript : Charles River Laboratories International, Inc. Presents at Baird's 2024 Global Healthcare Conference, Sep-10-2024 10:15 AM
09-05 Transcript : Charles River Laboratories International, Inc. Presents at Morgan Stanley 22nd Annual Global Healthcare Conference, Sep-05-2024 09:15 AM

Company Valuation: Charles River Laboratories International, Inc.

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 7,416 12,366 18,969 11,086 12,127 10,254 - -
Change - 66.75% 53.4% -41.55% 9.38% -15.44% - -
Enterprise Value (EV) 1 9,066 14,117 21,394 13,564 14,497 12,288 11,797 11,273
Change - 55.71% 51.55% -36.6% 6.88% -15.24% -4% -4.44%
P/E ratio 29.9x 34.5x 49.5x 23x 25.6x 31.6x 24.6x 19.6x
PBR 4.55x 5.85x 7.46x 3.73x 3.37x 2.59x 2.3x 2.05x
PEG - 0.8x 8.91x 0.9x -9.33x -1x 0.9x 0.8x
Capitalization / Revenue 2.83x 4.23x 5.36x 2.79x 2.94x 2.57x 2.47x 2.29x
EV / Revenue 3.46x 4.83x 6.04x 3.41x 3.51x 3.07x 2.84x 2.52x
EV / EBITDA 15x 20.1x 24.3x 13.7x 14.3x 12.3x 11.1x 9.72x
EV / EBIT 18.2x 24.1x 28.8x 16.3x 17.3x 15.5x 14.1x 12.2x
EV / FCF 26.6x 37.1x 40.2x 46x 39.7x 29.7x 25x 21.4x
FCF Yield 3.75% 2.69% 2.49% 2.17% 2.52% 3.37% 3.99% 4.68%
Dividend per Share 2 - - - - - - - -
Rate of return - - - - - - - -
EPS 2 5.07 7.2 7.6 9.48 9.22 6.292 8.068 10.15
Distribution rate - - - - - - - -
Net sales 1 2,621 2,924 3,540 3,976 4,129 3,996 4,152 4,477
EBITDA 1 604.4 701.3 879.5 990.9 1,013 996.5 1,059 1,160
EBIT 1 497.2 585 742.1 834 838.8 793 838.5 926
Net income 1 252 364.3 391 486.2 474.6 321.7 432.4 532.6
Net Debt 1 1,650 1,751 2,425 2,477 2,370 2,034 1,542 1,019
Reference price 2 151.84 248.59 375.88 217.90 236.40 198.61 198.61 198.61
Nbr of stocks (in thousands) 48,839 49,743 50,464 50,879 51,297 51,631 - -
Announcement Date 11/02/20 17/02/21 16/02/22 22/02/23 14/02/24 - - -
1USD in Million2USD
Estimates

P/E ratio, Detailed evolution

Add to a list
Add to a list

0 selected

To use this feature you must be a member
Log inSign up
 P/E ratio EV / Sales EV / EBITDA Yield (Y) Capi. ($)
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
31.57x3.07x12.33x-.--%10.25B
LONZA GROUP AG Stock Lonza Group AG
48.04x6.43x22.59x+0.83%47.27B
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
30.98x3.57x14.85x-.--%43.52B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-109.49x14.73x-252.01x-.--%34.06B
CELLTRION, INC. Stock Celltrion, Inc.
76.08x11.54x39.84x+0.26%30.33B
MODERNA, INC. Stock Moderna, Inc.
-7.17x6.1x-5.41x-.--%26.25B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
32.44x3.19x14.77x-.--%24.84B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
13.7x4.51x8.79x-.--%15.09B
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
62.15x9.65x27.53x+0.43%11.84B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
30.35x4.75x22.79x-.--%10.88B
Average 20.87x 6.75x -9.39x +0.15% 25.43B
Weighted average by Cap. 17.35x 7.14x -18.09x +0.20%
See all sector valuations

Income Statement and Estimates

More financial data

Year-on-year evolution of the PER

Historical PBR trend

Evolution Enterprise Value / Sales

Change in Enterprise Value/EBITDA

Year-on-year evolution of the Yield

  1. Stock Market
  2. Equities
  3. CRL Stock
  4. Valuation Charles River Laboratories International, Inc.
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW
United States

MarketScreener is also available in this country: United States.

Switch edition
Stay in the current country edition